Loading...
TARBP2-Enhanced Resistance during Tamoxifen Treatment in Breast Cancer
Tamoxifen is the most widely used hormone therapy in estrogen receptor-positive (ER+) breast cancer, which accounts for approximately 70% of all breast cancers. Although patients who receive tamoxifen therapy benefit with respect to an improved overall prognosis, resistance and cancer recurrence sti...
Saved in:
| Published in: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6406945/ https://ncbi.nlm.nih.gov/pubmed/30759864 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11020210 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|